Scinai Immunotherapeutics (FRA:2F5) Moat Score: 3/10 (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2F5 Scinai Immunotherapeutics Ltd FRA:2F5
20 GF Score
Price €0.21
! 4 Warning Signs
View Full Analysis

What is Scinai Immunotherapeutics Moat Score?

Scinai Immunotherapeutics FRA:2F5 -0.94% 20 Moat Score is 3 as of Jul. 26, 2026. GuruFocus rates FRA:2F5 with a GF Score™ of 20/100. The stock has 4 warning signs investors should review. Among 1,396 Biotechnology companies, Scinai Immunotherapeutics ranks better than 75.64% on this metric.

Scinai Immunotherapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Scinai Immunotherapeutics has No Moat: Scinai Immunotherapeutics Ltd lacks significant market leadership or customer loyalty. The company does not possess strong intellectual property or regulatory barriers, and its pricing power and distribution network are limited. Its competitive advantages are weak and transient.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Scinai Immunotherapeutics might have No Moat - Very weak/transient advantages.

Scinai Immunotherapeutics  (FRA:2F5) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Scinai Immunotherapeutics Moat Score Related Terms

FRA:2F5 vs ABPO, ISCO, ZVSA: Moat Score Comparison

For the Biotechnology subindustry, Scinai Immunotherapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scinai Immunotherapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's Moat Score falls into.


FRA:2F5
20GF Score
Scinai Immunotherapeutics Ltd FRA:2F5
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Scinai Immunotherapeutics (FRA:2F5) has a Moat Score of 3 as of Jul. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Scinai Immunotherapeutics ranks #340 out of 1396 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Scinai Immunotherapeutics' Moat Score too high?
Scinai Immunotherapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Scinai Immunotherapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Scinai Immunotherapeutics ranks #340 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Scinai Immunotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scinai Immunotherapeutics' Moat Score compare to ABPO and ISCO?
According to the Biotechnology industry distribution chart, Scinai Immunotherapeutics ranks #340 out of 1396 companies for Moat Score. This places Scinai Immunotherapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Scinai Immunotherapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinai Immunotherapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinai Immunotherapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinai Immunotherapeutics stock overvalued right now?
Scinai Immunotherapeutics (FRA:2F5) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Scinai Immunotherapeutics' overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Scinai Immunotherapeutics (FRA:2F5), the current Moat Score is 3 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scinai Immunotherapeutics Business Description

Other Exchanges SCNI:USA
Address Hadassah Ein Kerem Campus, 2nd Floor, Jerusalem BioPark, Jerusalem, ISR
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
20GF Score

Get the complete analysis for FRA:2F5

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.21
Price